ストックスクリーナーアプリを入手
0.8911
0.55%
0.0059
前日終値:
$0.8852
開ける：
$0.91
24時間の取引高:
170.68K
Relative Volume:
0.35
時価総額：
$11.47M
収益：
-
当期純損益:
$-19.86M
株価収益率:
-0.132
EPS:
-6.7506
ネットキャッシュフロー:
$-24.59M
1週間 パフォーマンス:
+5.34%
1か月 パフォーマンス:
-65.37%
6か月 パフォーマンス:
-92.43%
1年 パフォーマンス:
-93.72%
1日の値動き範囲:
$0.8849
$0.92
1週間の範囲:
$0.76
$0.92
52週間の値動き範囲:
$0.59
$23.20
Reviva Pharmaceuticals Holdings Inc Stock (RVPH) Company Profile
名前
Reviva Pharmaceuticals Holdings Inc
セクター
電話
(408) 501-8881
住所
10080 N WOLFE ROAD, CUPERTINO
Compare RVPH vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
RVPH
Reviva Pharmaceuticals Holdings Inc
|
0.8954 | 11.34M | 0 | -19.86M | -24.59M | -6.7506 |
VRTX
Vertex Pharmaceuticals Inc
|
439.92 | 112.35B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
748.03 | 79.71B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
835.59 | 52.29B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
326.33 | 44.48B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
321.26 | 35.51B | 5.36B | 287.73M | 924.18M | 2.5229 |
Reviva Pharmaceuticals Holdings Inc Stock (RVPH) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-05 | ダウングレード | D. Boral Capital | Buy → Hold |
| 2025-09-29 | 開始されました | Chardan Capital Markets | Buy |
| 2023-09-20 | 開始されました | ROTH MKM | Buy |
| 2023-06-08 | 開始されました | The Benchmark Company | Speculative Buy |
| 2022-01-24 | 開始されました | H.C. Wainwright | Buy |
Reviva Pharmaceuticals Holdings Inc (RVPH) 最新ニュース
Reviva Announces Letter to Shareholders - Sahm
Reviva Pharmaceuticals raises $10M, extends cash runway to Q1 2027 - Investing.com Australia
Reviva Pharmaceuticals Holdings (RVPH) price target increased by 14.00% to 77.52 - MSN
Reviva Pharmaceuticals Pursues Patent Extension for Brilaroxazine to 2046 and Prepares for Key FDA Milestone in Schizophrenia Program - Minichart
Reviva Pharmaceuticals outlines patent and development plans for brilaroxazine By Investing.com - Investing.com Australia
Reviva Updates Brilaroxazine Strategy and Funding Outlook - TipRanks
Reviva Announces patent filing, FDA alignment plans and RECOVER-2 timing - TradingView — Track All Markets
Reviva (NASDAQ: RVPH) maps brilaroxazine IP push and Phase 3 timeline - Stock Titan
$23M on hand, patent push: Reviva lays out 2026 drug roadmap - Stock Titan
Aug Weekly: Is Reviva Pharmaceuticals Holdings Inc forming a bullish divergencePortfolio Gains Report & AI Enhanced Trading Alerts - baoquankhu1.vn
Growth Report: Can Reviva Pharmaceuticals Holdings Inc sustain earnings growthMarket Risk Report & Risk Controlled Stock Pick Alerts - baoquankhu1.vn
Reviva Pharmaceuticals Holdings, Inc. (RVPHW) - Minichart
RVPH Should I Buy - Intellectia AI
Does Cobenfy Have the Potential to Become a Top Drug for BMY? - TradingView
Reviva Pharmaceuticals Holdings (RVPH) price target decreased by 42.03% to 68.00 - MSN
What date does Reviva Pharmaceuticals's (RVPH) report EarningsEarnings Calendar & Announcement - Zacks Investment Research
Maxim Group downgrades Reviva Pharmaceuticals Holdings (RVPH) - MSN
Short Squeeze: How do insiders feel about Reviva Pharmaceuticals Holdings Inc2026 Retail & Expert Approved Momentum Ideas - baoquankhu1.vn
Investment Recap: Is Reviva Pharmaceuticals Holdings Inc Equity Warrant being accumulated by smart money2026 PreEarnings & Free Real-Time Market Sentiment Alerts - baoquankhu1.vn
Energy Moves: Is Reviva Pharmaceuticals Holdings Inc Equity Warrant impacted by rising rates2026 Performance Recap & Reliable Breakout Forecasts - baoquankhu1.vn
Volume Summary: Will Reviva Pharmaceuticals Holdings Inc Equity Warrant outperform during market rallies2026 Technicals & Expert-Curated Trade Recommendations - baoquankhu1.vn
Aug Analyst Calls: Is now the right time to enter Reviva Pharmaceuticals Holdings Inc2026 Macro Impact & Weekly Return Optimization Plans - baoquankhu1.vn
Form S-3Registration statement under Securities Act of 1933 - ADVFN
Reviva Pharmaceuticals Holdings, Inc. (RVPHW) Fundamental Analysis - Meyka
RVPH|Reviva Pharmaceuticals Holdings Inc|Price:0.720|Chg%:-0.09 - TradingKey
Roth MKM Maintains Reviva Pharmaceuticals(RVPH.US) With Buy Rating, Maintains Target Price $1 - Moomoo
RVPH: Cleared for Takeoff – 2Q:26 Initiation of RECOVER 2 - Yahoo Finance
Roth MKM Maintains Reviva Pharmaceuticals(RVPH.US) With Buy Rating, Cuts Target Price to $1 - Moomoo
Aug Wrap: Is Reviva Pharmaceuticals Holdings Inc Equity Warrant in a bullish channel2026 Final Week & High Conviction Investment Ideas - baoquankhu1.vn
Portfolio Recap: Is now the right time to enter Reviva Pharmaceuticals Holdings Inc2026 Price Targets & Low Risk High Reward Trade Ideas - baoquankhu1.vn
Reviva Pharmaceuticals advances schizophrenia drug with new trial plans - Intellectia AI
Market Wrap: How do insiders feel about Reviva Pharmaceuticals Holdings Inc Equity WarrantDollar Strength & High Accuracy Swing Entry Alerts - baoquankhu1.vn
Integrated/Millennium group reports 6.2% stake in Reviva (RVPH) via 13G - Stock Titan
Reviva Pharmaceuticals Reports 2025 Financial Results and Corporate Updates, Including Brilaroxazine Progress and Patent Portfolio Expansion - Minichart
Reviva Pharmaceuticals 2025 Financial Review - AlphaStreet
Reviva Pharmaceuticals Advances Brilaroxazine for Schizophrenia: Clinical Trial Results, Pipeline, and Future Outlook - Minichart
Reviva Reports Positive 2025 Results, Plans Next Phase 3 Trial for Schizophrenia Drug - National Today
Reviva Reports Full Year 2025 Financial Results and Recent Business Highlights - The Manila Times
Reviva Pharmaceuticals Holdings 2025 10-K: Net Loss $0.20/share; Cash $14.44M - TradingView — Track All Markets
RVPH: Net loss narrowed in 2025 as brilaroxazine advanced toward a pivotal Phase 3 trial and regulatory milestones - TradingView — Track All Markets
Reviva (RVPH) trims 2025 loss as it readies RECOVER-2 Phase 3 for brilaroxazine - Stock Titan
RVPH: Net loss improved to $19.9M in 2025; cash sufficient into early 2027, but more funding required - TradingView — Track All Markets
Reviva Pharmaceuticals Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Published on: 2026-03-30 09:13:20 - baoquankhu1.vn
Reviva Pharmaceuticals Holdings (RVPH) price target increased by 2,046.68% to 117.30 - MSN
Top 10 stocks under $5 that could triple - MSN
Reviva Pharmaceuticals Holdings, Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
Analysts remain confident in Reviva Pharmaceuticals Holdings (RVPH) amid 1-for-20 reverse stock split - MSN
Targets Report: Is Reviva Pharmaceuticals Holdings Inc Equity Warrant stock showing strong momentumChart Signals & Safe Swing Trade Setups - baoquankhu1.vn
Growth Recap: Will Reviva Pharmaceuticals Holdings Inc benefit from green energy policiesGDP Growth & AI Based Buy/Sell Signal Reports - baoquankhu1.vn
Reviva Pharmaceuticals Holdings Inc expected to post a loss of $1.17 a shareEarnings Preview - TradingView
Reviva Pharmaceuticals Holdings Inc (RVPH) 財務データ
収益
当期純利益
現金流量
EPS
1.33%
1.07%
大文字化:
|
ボリューム (24 時間):